drugset / Trial / NCT01958060

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

NCT01958060 ↗

Phase 1 Terminated 35 enrolled Boehringer Ingelheim
RandomizedSingle-groupSingle-blindTreatment

Summary

Investigation of safety and tolerability of BI 1034020 in healthy male volunteers following intravenous (IV) infusion of subcutaneous (SC) injection of single doses and exploration of the pharmacokinetics and pharmacodynamics of BI 1034020 after single dosing and determination of the bioavailability of subcutaneous injections of BI 1034020

Timeline

Start
2013-10
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1034020 Unknown — Intravenous

Indications

No indication recorded.